Traditional Chinese Medicine (TCM), as a treasure of the Chinese nation, plays a significant role in maintaining public health. In 2019, the Central Committee of the Communist Party of China and the State Council proposed for the first time the establishment of a TCM registration and evaluation evidence system that integrates TCM theory, "personal experience" and clinical trials (referred to as the "Three-in-One" System) to promote the inheritance and innovation of TCM. Subsequently, the National Medical Products Administration issued several guiding principles to advance the improvement and implementation of this system. Owing to the complexity of its implementation, there are still differing understandings within the TCM industry regarding the positioning of the "Three-in-One" Registration and Evaluation Evidence System, as well as the connotation and value orientation of the "personal experience." To address this, Academician WANG Qi, President of the TCM Association, China International Exchange and Promotion Association for Medical and Healthcare and TCM master, led a group of academicians, TCM masters, TCM pharmacology experts and clinical TCM experts to convene a "Seminar on Promoting the Implementation of the ′Three-in-One′ Registration and Evaluation Evidence System for Chinese Medicinals." Through extensive discussions, an expert consensus was formed, clarifying the different roles of the TCM theory, "personal experience" and clinical trials within the system. It was further emphasized that the "personal experience" is the core of this system, and its data should be derived from clinical practice scenarios. In the future, the improvement of this system will require collaborative efforts across multiple fields to promote the high-quality development of the Chinese medicinal industry.

Objective To compare the clinical effect of first-line chemotherapy containing oxaliplatin on left and right colon cancer.Methods A total of 120 patients with colon cancer admitted to Second Affiliated Hospital of Shanghai University from January 2020 to January 2024 were selected and divided into left colon cancer group(60 cases)and right colon cancer group(60 cases)according to tumor location.Both groups were treated with first-line chemotherapy containing oxaliplatin for 2 cycles.Disease control rate,serum tumor markers,serum inflammatory factors,cancer-causing symptom scores,quality of life and incidence of adverse reactions were compared between two groups.Results After treatment,disease control rate in left colon cancer group was significantly higher than that in right colon cancer group(x2=22.224,P＜0.00 1).The levels of serum carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 153,C-reactive protein and interleukin-6 of left colon cancer group were lower than those of right colon cancer group(P＜0.05).The scores of cancer-related pain and fatigue of left colon cancer group were lower than those of right colon cancer group(P＜0.05).The quality of life in left colon cancer group was better than that in right colon cancer group(P＜0.05).Conclusion First-line chemotherapy containing oxaliplatin has better short-term efficacy in patients with left colon cancer,with better control of tumor progression,and can improre clinical symptoms and quality of life.